Pay in 4 interest-free payments of $5.75 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Retatrutide (LY3437943) is Eli Lillys experimental triple-agonist drug that activates: GLP-1 (Glucagon-like peptide-1) reduces appetite and slows digestion GIP (Glucose-dependent insulinotropic peptide) enhances insulin sensitivity Glucagon receptor increases fat metabolism and energy expenditure In phase-2 trials, Retatrutide achieved up to 24% body-weight reduction rivaling or even surpassing bariatric surgery outcomes
:
Not combinable with CARTBOGO or other BOGO-style promotions
10.1155/2019/9084643 67 KraljT.KokotA.KasnikK.DrmicD.ZlatarM.SeiwerthS.et al (2017)
Functionally all of these phenotypes are characterised by loss of several homoeostatic molecules, which decreases neuronal support and neuroprotection ultimately resulting in neuronal death
US$ 24.18
US$ 24.97
US$ 29.17
US$ 24.95
US$ 28.95
US$ 25.70
US$ 27.17
